Cancer Science & Therapy

Józef Oleksyszyn

Jozef Oleksyszyn Wrocław University of Technology USA Tel: 320 40 27

Biography

Prof. Józef Oleksyszyn has recived his Ph.D. (1974-1977) and D.S. (doctor of sciences, habilitation, 1978-1986) from Faculty of Chemistry, WrocÅ‚aw University of Technology. Currently he is professor of biochemistry at that place. Two postdoctoral scholarship. The first (1982-1984) at Department of Chemistry, Michigen University with prof. Arthur Ashe and the second one at Georgia Institute of Technology with prof. James C. Powers. During the period of 1990-2000 has been working in few biotechnology companies including CORTECH Inc., (Denver,CO), OsteoArthritis Inc., (Boston, MA) and DYAX (Boston, MA), at positions from research scientist to the Director of Chemical Sciences. One of the compounds, inhibitor of human neutrophil elastase, designed and synthesized by him went to clinical trial (Cortech). He discovered an amidoalkylation reaction of trivalent phosphorus derivatives, named in literature sometimes “Oleksyszyn reaction”. In prof. Powers lab he discovered a new class of selective and potent, serine protease inhibitors – diaryl 1-aminoalkylphosphonates. In 2002 he returned to WrocÅ‚aw Technology University, where he build-up the Division of Medicinal Chemistry and Microbiology that he has been headed during the period 2006-2011. His research resulted in more than 70 publications in reputed journals and more than 50 patents and patents applications, including 8 USA patents. His is a member of American Chemical Society. His is serving as editorial member of several reputed journal like Journal Anti-cancer Agents in Medicinal Chemistry, American Journal of Cancer Prevention, Journal of Pharmacological & Biomedical Analysis, Cell Biology:Research & Therapy, and expert Revivers for several Journals. His research interest include a new approaches for the anticancer therapies, enzyme inhibitors as a new drugs, including new antibacterial drugs, inhibitors of proteolytic enzymes as new drug generation.

Research Interest

Anticancer therapies, enzyme inhibitors as a new drugs, including new antibacterial drugs, inhibitors of proteolytic enzymes as new drug generation